Endeavor BioMedicines

San Diego, CA · Founded 2018 · Biotech · Private

Small-molecule and biologic therapeutics for life-threatening diseases

Claim this profile

Follows are private to you and power your alerts

Updated · endeavorbio.com

Sector
Biotech
Headquarters
San Diego, CA
Founded
2018
Latest Form D
$133M, May 2024
Total capital
$222M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$222M
2 Form D · last May 2024
30 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
7
15 pending · first 2023
Rank in peer group#213 of 1449

Capital timeline

202220232024FEDERAL ↑EQUITY ↓Cumulative $222M1st Form D$89.1M2nd Form D$133M
202220232024FEDERAL ↑EQUITY ↓Cumulative $222M1st Form D$89.1M2nd Form D$133M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$133M
  • Private capital raisedForm D · SEC · 1st filing$89.1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 1449 peers

Line = median

Biotech · Molecule

  • Granted patents#213 · top 15%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants
  • Miguel de los RiosResearcherExecutive OfficerLinked by 6 patents
  • Bernard DavitianDirectorNamed in SEC Form D filings
  • Chris KruegerExecutive OfficerNamed in SEC Form D filings
  • Enoch KariukiExecutive OfficerNamed in SEC Form D filings
  • John HoodExecutive Officer, DirectorNamed in SEC Form D filings
  • Karan Cheong TakharDirectorNamed in SEC Form D filings
Show all 11 people
  • Monal Cheong MehtaDirectorNamed in SEC Form D filings
  • Patrick G. EnrightDirectorNamed in SEC Form D filings
  • Raghu SaripalliExecutive OfficerNamed in SEC Form D filings
  • Vishaal TurakhiaExecutive OfficerNamed in SEC Form D filings
  • Wing Cheong LamDirectorNamed in SEC Form D filings

What it has protected

USPTO · 7 granted of 22
Show all 22 patent records
  • Methods Of Improving Lung FunctionApr 21, 2026 · US 12,605,379Granted
  • Methods Of Treating FibrosisApr 21, 2026 · US 12,605,377Granted
  • Methods Of Improving Lung FunctionApr 21, 2026 · US 12,605,380Granted
  • Methods Of Improving Lung FunctionOct 21, 2025 · US 12,447,148Granted
  • Methods Of Treating FibrosisJul 24, 2025 · Application 19177041Pending
  • Methods Of Treating FibrosisMay 13, 2025 · US 12,295,954Granted
  • Methods Of Treating FibrosisFeb 4, 2025 · US 12,213,974Granted
  • Method Of Treating Cancer Having An Activated Hedgehog PathwayJun 15, 2023 · Application 18078655Pending
  • Method Of Treating FibrosisApr 18, 2023 · US 11,628,167Granted
  • Method Of Treating Cancer Having An Activated Hedgehog PathwayApplication 63315803Pending
  • Method Of Treating Cancer Having An Activated Hedgehog PathwayApplication 63287832Pending
  • Method Of Treating FibrosisApplication PCTUS2021054713Pending
  • Methods Of Treating FibrosisApplication 19679193Pending
  • Methods Of Treating FibrosisApplication 63091128Pending
  • Methods Of Treating FibrosisApplication PCTUS2025018800Pending
  • Methods Of Improving Lung FunctionApplication PCTUS2025018407Pending
  • Methods Of Improving Lung FunctionApplication 63711648Pending
  • Methods Of Improving Lung FunctionApplication 63649067Pending
  • Methods of Treating FibrosisApplication 63562488Pending
  • Methods And Compositions For Treating Pulmonary FibrosisApplication 63561444Pending
  • Methods Of Treating FibrosisApplication PCTUS2024017611Pending
  • Method Of Treating Cancer Having An Activated Hedgehog PathwayApplication PCTUS2022081299Pending
  • Seaport TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Rivus PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
  • Cyclerion Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • AbsciSimilar federal contract value in Biotech · null in contracts
  • Generation BioSimilar federal contract value in Biotech · null in contracts
  • Renibus Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .